Bayer has had a tumultuous run, with its shares currently near a
20-year low following a negative forecast for 2025 earnings. The
pharmaceutical giant's stocks have experienced considerable dips, largely attributed to weak Q3 performances, guidance cuts, and warnings from its crop-sciences unit. A U.S. court review of the Monsanto case led to a 7% fall in share price. Meanwhile, CEO Bill Anderson admitted the company's earnings are
'Not Pretty', while shareholders are pressing for fast changes given the lowest point in 20 years. Conversely, the stock did exhibit signs of recovery in brief stints, such as an 11% surge following a U.S. legal win against Roundup cancer claims. Investors have also been encouraged as the
BAYER Stocks was assessed for upside potential after Q3 reports. The acquisition of
cardiovascular drug rights from CYTK in Japan marked an important development, while a FDA acceptance of Bayer's application for label expansion of Nubeqa was seen as positive. Despite facing losses, Bayer illustrated signs of resilience, hinted at the prospect of internal restructuring to face the weak
agriculture market, and was also observed to leverage AI to combat herbicide resistance.
BAYER Stocks News Analytics from Thu, 18 Jan 2024 08:00:00 GMT to Fri, 06 Dec 2024 08:08:22 GMT -
Rating -7
- Innovation 3
- Information 5
- Rumor -5
